Evidence map›Paper›PMID 42446547›Full record

ReviewMedicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents2026

Pyridine-containing antitumor agents: structure-oriented medicinal chemistry, structure-activity relationships, and ADMET liabilities.

Wei Zhao, Beibei Bie, Juning Wang, Xueying Liu, Huanle Fang, Rui Niu

Abstract readReview
In one paragraph

Review in Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wei ZhaoSchool of Medicine, Xi'an Peihua University, Xi'an, 710125, China. 004157@peihua.edu.cn.
Beibei BieSchool of Medicine, Xi'an Peihua University, Xi'an, 710125, China.
Juning WangSchool of Medicine, Xi'an Peihua University, Xi'an, 710125, China.
Xueying LiuSchool of Medicine, Xi'an Peihua University, Xi'an, 710125, China.
Huanle FangSchool of Medicine, Xi'an Peihua University, Xi'an, 710125, China.
Rui NiuSchool of Medicine, Xi'an Peihua University, Xi'an, 710125, China.

Funding

Natural Science Special Research Program of the Education Department of Shaanxi Province 25JK0596
6 · The paper itself

Abstract

Pyridine is a common nitrogen-containing heteroaromatic motif in antitumor medicinal chemistry, but its design value is highly context dependent. Here, we synthesize structure-oriented medicinal chemistry principles that govern the use of pyridine-related motifs in antitumor drug design. We discuss pyridine-containing antitumor agents with emphasis on target recognition, scaffold organization, structure-activity relationship (SAR), drug metabolism and pharmacokinetics (DMPK), and absorption, distribution, metabolism, excretion, and toxicity (ADMET) liabilities. Representative approved drugs, antibody-drug conjugate (ADC) payloads, targeted degraders, and polypyridyl metal complexes are used to illustrate how pyridine-related motifs can support binding, property tuning, and modality adaptation. By grouping representative compounds according to the medicinal chemistry function of their pyridine-related motifs, this review provides a practical framework for future scaffold design. Overall, pyridine should not be viewed as a universally beneficial privileged scaffold; it is better treated as a context-dependent design module that requires validation through integrated structural, SAR, ADMET, and translational evidence.

Indexed as

Antineoplastic AgentsPyridinesAnimalsChemistry, PharmaceuticalDrug DesignHumansStructure-Activity RelationshipAntineoplastic AgentspyridinePyridinesADMETAntitumor agentsMedicinal chemistryPyridineStructure–activity relationshipTargeted protein degradation

Identifiers

PMID42446547
PMCPMC13385078

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.